Xianle Health (300791.SZ) released its 2023 annual report. The company achieved operating income of 35 during the reporting period...
According to Zhitong Finance App, Xianle Health (300791.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 3,582 billion yuan, an increase of 42.87%; net profit attributable to shareholders of listed companies was 281 million yuan, up 32.39% year on year; net profit attributable to shareholders of listed companies deducted non-recurring profit and loss of 281 million yuan, an increase of 43.01% year on year; basic earnings per share were 1.5585 yuan/share.
The company's profit distribution plan was reviewed and approved by the current board of directors: based on the total share capital registered on the equity distribution registration date after deducting the shares already repurchased in the company's special account, a cash dividend of 11 yuan (tax included) is distributed to all shareholders for every 10 shares. At the same time, a capital reserve fund is used to transfer 3 shares for every 10 shares to all shareholders without bonus shares.
During the reporting period, among the main businesses, the domestic business achieved sales revenue of 1,851 billion yuan, an increase of 24.11% over the previous year, further increasing the market share; the overseas business achieved sales revenue of 1,731 billion yuan, an increase of 70.40% over the previous year, increasing the market penetration rate.